Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
224.9
USD
|
+2.21%
|
|
+3.27%
|
-13.07%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
53,543
|
37,679
|
35,242
|
39,877
|
37,495
|
32,751
|
-
|
-
|
Enterprise Value (EV)
1 |
51,733
|
41,723
|
37,820
|
40,560
|
43,384
|
35,745
|
33,364
|
29,750
|
P/E ratio
|
9.44
x
|
9.87
x
|
23.1
x
|
13.3
x
|
32.5
x
|
17.4
x
|
14.9
x
|
12.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.72
x
|
2.8
x
|
3.21
x
|
3.92
x
|
3.81
x
|
3.44
x
|
3.43
x
|
3.31
x
|
EV / Revenue
|
3.6
x
|
3.1
x
|
3.44
x
|
3.99
x
|
4.41
x
|
3.75
x
|
3.49
x
|
3.01
x
|
EV / EBITDA
|
6.41
x
|
5.56
x
|
9.13
x
|
11.2
x
|
14.3
x
|
10.7
x
|
9.28
x
|
7.42
x
|
EV / FCF
|
7.88
x
|
11
x
|
11.2
x
|
35.5
x
|
34.2
x
|
15.8
x
|
11.9
x
|
10.2
x
|
FCF Yield
|
12.7%
|
9.12%
|
8.94%
|
2.82%
|
2.93%
|
6.34%
|
8.37%
|
9.77%
|
Price to Book
|
3.87
x
|
3.7
x
|
3.26
x
|
3.02
x
|
2.53
x
|
1.93
x
|
1.7
x
|
1.49
x
|
Nbr of stocks (in thousands)
|
180,442
|
153,882
|
146,893
|
144,001
|
144,898
|
145,597
|
-
|
-
|
Reference price
2 |
296.7
|
244.9
|
239.9
|
276.9
|
258.8
|
224.9
|
224.9
|
224.9
|
Announcement Date
|
1/30/20
|
2/3/21
|
2/3/22
|
2/15/23
|
2/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
14,378
|
13,445
|
10,982
|
10,173
|
9,836
|
9,520
|
9,561
|
9,892
|
EBITDA
1 |
8,070
|
7,504
|
4,144
|
3,618
|
3,040
|
3,333
|
3,594
|
4,008
|
EBIT
1 |
7,390
|
6,837
|
3,656
|
3,099
|
2,545
|
2,873
|
3,077
|
3,357
|
Operating Margin
|
51.4%
|
50.85%
|
33.3%
|
30.47%
|
25.87%
|
30.18%
|
32.19%
|
33.93%
|
Earnings before Tax (EBT)
1 |
7,126
|
5,048
|
1,745
|
3,592
|
1,297
|
2,306
|
2,810
|
3,368
|
Net income
1 |
5,888
|
4,001
|
1,556
|
3,047
|
1,161
|
1,925
|
2,235
|
2,654
|
Net margin
|
40.96%
|
29.76%
|
14.17%
|
29.95%
|
11.8%
|
20.22%
|
23.38%
|
26.83%
|
EPS
2 |
31.42
|
24.80
|
10.40
|
20.87
|
7.970
|
12.96
|
15.09
|
18.35
|
Free Cash Flow
1 |
6,564
|
3,805
|
3,382
|
1,144
|
1,270
|
2,267
|
2,794
|
2,906
|
FCF margin
|
45.65%
|
28.3%
|
30.8%
|
11.25%
|
12.91%
|
23.82%
|
29.22%
|
29.37%
|
FCF Conversion (EBITDA)
|
81.34%
|
50.71%
|
81.61%
|
31.62%
|
41.79%
|
68.03%
|
77.73%
|
72.5%
|
FCF Conversion (Net income)
|
111.47%
|
95.11%
|
217.34%
|
37.55%
|
109.4%
|
117.81%
|
124.98%
|
109.48%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/30/20
|
2/3/21
|
2/3/22
|
2/15/23
|
2/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
2,734
|
2,532
|
2,589
|
2,508
|
2,544
|
2,463
|
2,456
|
2,530
|
2,386
|
2,290
|
2,384
|
2,408
|
2,450
|
2,380
|
2,412
|
EBITDA
1 |
780.7
|
844.1
|
1,112
|
991
|
792.7
|
674.7
|
797.7
|
853.1
|
697.5
|
795.5
|
964.8
|
990.3
|
1,033
|
-
|
-
|
EBIT
1 |
646
|
708.6
|
976.7
|
870
|
672.9
|
467.5
|
674.2
|
728.1
|
557.4
|
648
|
721.7
|
734.7
|
728.4
|
719.3
|
755.9
|
Operating Margin
|
23.63%
|
27.99%
|
37.72%
|
34.68%
|
26.45%
|
18.98%
|
27.45%
|
28.78%
|
23.36%
|
28.29%
|
30.27%
|
30.52%
|
29.73%
|
30.23%
|
31.34%
|
Earnings before Tax (EBT)
1 |
405
|
347.4
|
1,270
|
1,371
|
603.8
|
438.3
|
708.1
|
-141.2
|
291.6
|
464.8
|
627.3
|
545
|
549.5
|
512.5
|
526.5
|
Net income
1 |
368.2
|
303.8
|
1,058
|
1,135
|
550.4
|
387.9
|
591.6
|
-68.1
|
249.7
|
393.4
|
525.9
|
481.4
|
490.1
|
458
|
488.3
|
Net margin
|
13.47%
|
12%
|
40.86%
|
45.23%
|
21.64%
|
15.75%
|
24.09%
|
-2.69%
|
10.47%
|
17.18%
|
22.06%
|
19.99%
|
20%
|
19.25%
|
20.24%
|
EPS
2 |
2.500
|
2.060
|
7.240
|
7.840
|
3.790
|
2.670
|
4.070
|
-0.4700
|
1.710
|
2.700
|
3.599
|
3.184
|
3.361
|
3.290
|
3.405
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/3/22
|
5/3/22
|
7/20/22
|
10/25/22
|
2/15/23
|
4/25/23
|
7/25/23
|
11/8/23
|
2/13/24
|
4/24/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
4,044
|
2,578
|
683
|
5,888
|
2,995
|
614
|
-
|
Net Cash position
1 |
1,810
|
-
|
-
|
-
|
-
|
-
|
-
|
3,000
|
Leverage (Debt/EBITDA)
|
-
|
0.5389
x
|
0.6221
x
|
0.1888
x
|
1.937
x
|
0.8986
x
|
0.1707
x
|
-
|
Free Cash Flow
1 |
6,564
|
3,805
|
3,382
|
1,144
|
1,270
|
2,267
|
2,794
|
2,906
|
ROE (net income / shareholders' equity)
|
47.7%
|
45.2%
|
26.6%
|
21.2%
|
15.2%
|
14.3%
|
14.6%
|
14.5%
|
ROA (Net income/ Total Assets)
|
24%
|
15.4%
|
11.9%
|
12.6%
|
4.52%
|
7.56%
|
7.57%
|
7.86%
|
Assets
1 |
24,583
|
25,927
|
13,124
|
24,216
|
25,699
|
25,445
|
29,512
|
33,771
|
Book Value Per Share
2 |
76.60
|
66.20
|
73.50
|
91.70
|
102.0
|
117.0
|
132.0
|
151.0
|
Cash Flow per Share
2 |
38.00
|
26.20
|
24.30
|
9.480
|
10.60
|
19.70
|
20.10
|
24.40
|
Capex
1 |
515
|
425
|
258
|
240
|
277
|
297
|
286
|
295
|
Capex / Sales
|
3.58%
|
3.16%
|
2.35%
|
2.36%
|
2.82%
|
3.12%
|
2.99%
|
2.98%
|
Announcement Date
|
1/30/20
|
2/3/21
|
2/3/22
|
2/15/23
|
2/13/24
|
-
|
-
|
-
|
Last Close Price
224.9
USD Average target price
284.8
USD Spread / Average Target +26.60% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.07% | 32.75B | | -2.29% | 89.87B | | -3.95% | 37.57B | | +63.05% | 26.47B | | -22.14% | 14.25B | | -7.96% | 12.99B | | -9.33% | 11.93B | | -46.33% | 10.84B | | +5.77% | 9.11B | | -17.66% | 7.32B |
Biopharmaceuticals
|